Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 6 through 23 months~2. Have evidence of AOM defined as:~   * recent (within 48 hours) onset of signs and symptoms as described in the Acute Otitis Media - Severity of Symptoms (AOM-SOS) Scale AND a score of ≥3 at the time of enrollment on the AOM-SOS scale~  * middle ear effusion evidenced by the presence of at least 2 of the following:~  * decreased or absent mobility of the tympanic membrane~  * yellow or white discoloration of the tympanic membrane~  * opacification of the tympanic membrane~   AND~  * acute inflammation evidenced by one of the following:~  * 1+ bulging of the tympanic membrane with either intense erythema or otalgia~  * 2+ or 3+ bulging of the tympanic membrane~3. Has received at least 2 doses of pneumococcal conjugate vaccine~4. Parent has provided informed consent~Exclusion Criteria:~1. Toxic appearance \[capillary refill \>3 seconds, systolic blood pressure \<60 mm Hg\];~2. Inpatient hospitalization~3. Clinical or anatomical characteristics that might obscure response to treatment (tympanostomy tubes in place, cleft palate, or Down syndrome)~4. Sensorineural hearing loss (unilateral or bilateral)~5. Serious underlying systemic problems that might obscure response to infection (cystic fibrosis, neoplasm, juvenile diabetes)~6. Concomitant infection that would preclude evaluation of the response of the child's AOM to study product (pneumonia, periorbital cellulitis)~7. Acute wheezing exacerbation which may require treatment with systemic corticosteroids~8. Known renal or hepatic dysfunction or insufficiency~9. History of amoxicillin-clavulanate-associated cholestatic jaundice~10. Immune dysfunction or receipt of immunosuppressive therapy; chronic gastrointestinal conditions (i.e., malabsorption, inflammatory bowel disease)~11. Co-medications (systemic corticosteroids, more than one dose of systemic antimicrobial therapy within 96 hours, receipt of any investigational drug or vaccine within 30 days)~12. Hypersensitivity to penicillin, amoxicillin or amoxicillin-clavulanate, or phenylketonuria or known hypersensitivity to aspartame~13. Unable to complete study, or no access to phone~14. Previously enrolled in this study or currently enrolled in another study

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 23 Months
- Healthy Volunteers: f

Study Arms:
- Amoxicillin-Clavulanate, 10 days (Type: ACTIVE_COMPARATOR): amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 10 days
- Amoxicillin-Clavulanate, 5 days (Type: OTHER): amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 5 days plus placebo, 2 divided doses, 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).